Publications by authors named "Fred McCall-Perez"
Article Synopsis
- Selegiline (L-deprenyl) is primarily used to treat Parkinson's disease as a selective, irreversible inhibitor of monoamine oxidase B (MAO-B) at standard doses, but higher doses show potential antidepressant effects by possibly inhibiting MAO-A as well.
- Zydis selegiline (Zelapar) is a fast-dissolving version that allows for better absorption, leading to increased plasma levels and fewer metabolite effects compared to regular selegiline; however, its selectivity for MAO-B may diminish at higher dosages.
- A study found that a 10 mg daily dose of Zydis selegiline significantly inhibited MAO-A in healthy men, providing the first direct
Efficacy and tolerability of a facial serum for fine lines, wrinkles, and photodamaged skin.
J Clin Aesthet Dermatol
July 2011
Background: Dermatology visits for the prevention and treatment of aging skin are rapidly increasing. The clinical sequelae including wrinkling, pigmentary changes, roughness, laxity, and telangiectasia can all result in the appearance of aging skin, impacting quality of life. A facial serum was developed with ingredients associated with an improvement in the appearance of fine lines and wrinkles and increase in stratum corneum barrier function.
View Article and Find Full Text PDF